secwatch / observer
8-K filed June 2, 2026, 4:45 PM ET ticker CUE CIK 0001645460
leadership confidence high sentiment neutral materiality 0.60

Cue Biopharma appoints new directors, chief legal officer, and accounting officer; board size reduced

Cue Biopharma, Inc.

item 5.02item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Patrick Verheyen

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Departed

Peter Kiener

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Appointed

Daniel Camardo

director
CUE · Cue Biopharma, Inc.
Effective
2026-05-30
Filed
June 2, 2026, 4:45 PM ET
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
Appointed

Viola Meehan

director
CUE · Cue Biopharma, Inc.
Effective
2026-05-30
Filed
June 2, 2026, 4:45 PM ET
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
Appointed

Michael Meluzio

Vice President, Principal Accounting Officer
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Filed
June 2, 2026, 4:45 PM ET
On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.
Appointed

Sumita Ray

Chief Legal & Compliance Officer and Corporate Secretary
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Filed
June 2, 2026, 4:45 PM ET
On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
Role change

Colin Sandercock

Senior Vice President, Intellectual Property
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Successor
Sumita Ray
Filed
June 2, 2026, 4:45 PM ET
Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.
Departed

Jill Broadfoot

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Departed

Frank Morich

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Patrick Verheyen departed as member of the Board of Directors at Cue Biopharma, Inc..

Action
resign
Role
member of the Board of Directors
Exact text from the filing
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Peter Kiener departed as member of the Board of Directors at Cue Biopharma, Inc..

Action
resign
Role
member of the Board of Directors
Exact text from the filing
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel Camardo was appointed as director at Cue Biopharma, Inc..

Action
appointed
Role
director
Exact text from the filing
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Viola Meehan was appointed as director at Cue Biopharma, Inc..

Action
appointed
Role
director
Exact text from the filing
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Meluzio was appointed as Vice President, Principal Accounting Officer at Cue Biopharma, Inc..

Action
appointed
Role
Vice President, Principal Accounting Officer
Exact text from the filing
On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Sumita Ray was appointed as Chief Legal & Compliance Officer and Corporate Secretary at Cue Biopharma, Inc..

Action
appointed
Role
Chief Legal & Compliance Officer and Corporate Secretary
Exact text from the filing
On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.9

Colin Sandercock changed role as Senior Vice President, Intellectual Property at Cue Biopharma, Inc..

Role
Senior Vice President, Intellectual Property
Exact text from the filing
Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Jill Broadfoot departed as member of the Board of Directors at Cue Biopharma, Inc..

Action
resign
Role
member of the Board of Directors
Exact text from the filing
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Frank Morich departed as member of the Board of Directors at Cue Biopharma, Inc..

Action
resign
Role
member of the Board of Directors
Exact text from the filing
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
View on SEC.gov

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-253709
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.